Yasuhiro Tsume Selected Research

Neoplasms (Cancer)

8/2017	Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
1/2017	Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
8/2015	In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
4/2014	The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
1/2014	The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.
8/2013	The extracellular microenvironment explains variations in passive drug transport across different airway epithelial cell types.
1/2012	Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates.
10/2011	Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.
9/2008	Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.
6/2008	Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuhiro Tsume Research Topics

Disease

11	Neoplasms (Cancer) 08/2017 - 11/2007
3	Human Influenza (Influenza) 02/2016 - 12/2011
2	Breast Neoplasms (Breast Cancer) 10/2018 - 01/2017
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2014 - 03/2012
1	Triple Negative Breast Neoplasms 01/2017
1	Ulcerative Colitis 01/2017
1	Infections 04/2013
1	Colorectal Neoplasms (Colorectal Cancer) 04/2011
1	Melanoma (Melanoma, Malignant) 11/2007
1	Weight Loss (Weight Reduction) 11/2007

Drug/Important Bio-Agent (IBA)

11	ProdrugsIBA 08/2017 - 11/2007
5	DipeptidesIBA 08/2017 - 09/2008
4	Amino Acids FDA Link 08/2017 - 09/2008
4	Floxuridine (FUdR)FDA LinkGeneric 01/2014 - 09/2008
3	Gemcitabine FDA Link 08/2017 - 01/2014
3	BuffersIBA 04/2014 - 09/2008
2	EnzymesIBA 08/2017 - 03/2012
2	AcidsIBA 08/2015 - 03/2012
2	Dosage Forms (Dosage Form)IBA 04/2014 - 01/2014
2	Fluorouracil (Carac)FDA LinkGeneric 04/2011 - 09/2008
1	diphenyl (biphenyl)IBA 10/2018
1	Valacyclovir (Valtrex)FDA LinkGeneric 10/2018
1	Valganciclovir FDA Link 10/2018
1	Acyclovir (Aciclovir)FDA LinkGeneric 10/2018
1	HydrolasesIBA 10/2018
1	Proteins (Proteins, Gene)FDA Link 10/2018
1	Serine (L-Serine)FDA Link 10/2018
1	Ganciclovir (Cytovene)FDA LinkGeneric 10/2018
1	Docetaxel (Taxotere)FDA Link 01/2017
1	Mesalamine (Mesalazine)FDA LinkGeneric 01/2017
1	sulforaphaneIBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	Taxoids (Taxanes)IBA 01/2017
1	Dasatinib (BMS 354825)FDA Link 08/2015
1	Reducing AgentsIBA 08/2015
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2015
1	Tyrosine Kinase InhibitorsIBA 08/2015
1	Propranolol (Inderal)FDA LinkGeneric 08/2013
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2013
1	Antiviral Agents (Antivirals)IBA 02/2013
1	Peptides (Polypeptides)IBA 02/2013
1	Zanamivir (Relenza)FDA Link 12/2011
1	5-fluoro-2'-deoxyuridineIBA 04/2011
1	Proline (L-Proline)FDA Link 11/2007
1	proline dipeptidase (prolidase)IBA 11/2007
1	prophalanIBA 11/2007
1	Melphalan (Alkeran)FDA LinkGeneric 11/2007

Therapy/Procedure

1	Therapeutics 08/2017
1	Drug Therapy (Chemotherapy) 01/2012